Complications from vascular disrupting agents and angiogenesis inhibitors: Aberrant control of hemostasis and thrombosis

Current Opinion in Hematology

Volumn 14, Issue 5, 2007, Pages 468-480

  Van Heeckeren, Willem J ^a,b   Sanborn, Sharon L ^a   Narayan, Ajita ^a   Cooney, Matthew M ^a   McCrae, Keith R ^a   Schmaier, Alvin H ^a   Remick, Scot C ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Angiogenesis inhibitor; Endothelial cell; Hemorrhage; Hemostasis; Thrombosis; Vascular disrupting agent

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; 4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ACETYLSALICYLIC ACID; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; AURISTATIN PE; AVE 8062A; BEVACIZUMAB; CHIR 258; COMBRETASTATIN; DEXAMETHASONE; ENDOSTATIN; EXHERIN; HEPARIN; KRN 951; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MN 029; N ACETYLCOLCHINOL PHOSPHATE; PAZOPANIB; PD 173074; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; SORAFENIB; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; VANDETANIB; VASCULAR TARGETING AGENT; VASCULOTROPIN; VATALANIB; WARFARIN;

ANGINA PECTORIS; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTERY THROMBOSIS; BLEEDING; FLUSHING; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEMOPTYSIS; HEMOSTASIS; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LUNG EMBOLISM; LUNG HEMORRHAGE; PATHOGENESIS; PHLEBITIS; PRIORITY JOURNAL; PROPHYLAXIS; QT PROLONGATION; REVIEW; RISK; SCREENING; SIDE EFFECT; STROKE; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTICOAGULANTS; ENDOTHELIUM, VASCULAR; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEMOSTASIS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RISK FACTORS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTORS; VENOUS THROMBOEMBOLISM;

EID: 34648827568     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3282a6457f     Document Type: Review

References (89)

1. Falanga A, Rickles F. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999; 25:173-182.
2. De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hemat 2004; 50:187-196.
3. Franchini M, Montagnana M, Targher G, et al. Pathogenesis, clinical and laboratory aspects of thrombosis in cancer. J Thromb Thrombolysis 2007; 24:29-38. This is an excellent, current review of mechanisms of cancer-associated thrombosis including management.
4. Michiels C. Endothelial cell functions. J Cell Physiol 2003; 196:430-443.
5. Verhamme P, Hoylaerts M. The pivotal role of the endothelium in haemostasis and thrombosis. Acta Clin Belg 2006; 61:213-219. This ia a good current review of endothelial cell biology and its relationship to hemostasis and thrombosis.
6. Winn R, Harlan J. The role of endothelial cell apoptosis in inflammatory and immune diseases. J Thromb Haemost 2005; 3:1815-1824.
7. Levitan N, Dowlati A, Remick S, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78:284-291.
8. Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998; 91:3093-3102.
9. Esmon C. The interactions between inflammation and coagulation. Br J Haematol 2005; 131:417-430.
10. Dameron K, Volpert O, Tainsky M, et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265:1582-1584.
11. Lamalice L, Le Boeuf F, Huot J. Endothelial cell migration during angiogenesis. Circ Res 2007; 100:782-794.
12. Jakob C, Sterz J, Zavrski I, et al. Angiogenesis in multiple myeloma. Eur J Cancer 2006; 42:1581-1590.
13. Otrock Z, Makarem J, Shamseddine A. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis 2007; 28:258-268. This is a good current review of VEGF and VEGFR biology.
14. Yang R, Thomas G, Bunting S, et al. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol 1996; 27:838-844.
15. Sahni A, Francis C. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood 2000; 96:3772-3778.
16. Sudhakar A, Sugimoto H, Yang C, et al. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci USA 2003; 100:4766-4771.
17. Kim Y, Hwang S, Kim Y, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 2002; 277:27872-27879.
18. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006; 28:1179-1802. This is an excellent review of current use of bevacizumab for solid tumors, possible future directions in clinical trials, and pathophysiology.
19. Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006; 33:S26-S34.
20. Sandler A, Gray R, Perry M, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-2550.
21. Johnson D, Fehrenbacher L, Novotny W, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic nonsmall-cell lung cancer. J Clin Oncol 2004; 22:2184-2191.
22. Mulay M, Limentani S, Carroll M, et al. Safety and pharmacokinetics of intravenous VEGF Trap plus FOLFOX4 in a combination phase I clinical trial of patients with advanced solid tumors. J Clin Oncol (ASCO Annual Meeting Proceedings I) 2006; 24:18S, abstract 13061.
23. Rixe O, Verslype C, Meric J, et al. Safety and Pharmacokinetics of Intravenous VEGF trap plus irinotecan, 5-fluorouracil, and leucovorin in a combination phase I clinical trial of patients with advanced solid tumors. J Clin Oncol (ASCO Annual Meeting Proceedings I) 2006; 24:18S, abstract 13161.
24. Escudier B, Szczylik C, Demkow T, et al. Randomized phase II trial of the multikinase inhibitor sorafenib versus interferon in treatment naïve patients with metastatic renal cell carcinoma. J Clin Oncol (ASCO Annual Meeting Proceedings I) 2006; 24:18S, abstract 4501.
25. Escudier B, Eisen T, Stadler W, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134.
26. Motzer R, Michaelson M, Redman B, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:16-24.
27. Motzer R, Rini B, Bukowski R, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295:2516-2524.
28. Goodman V, Rock E, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007; 13:1367-1373.
29. Scott E, Meinhardt G, Jacques C, et al. Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours. Expert Opin Invest Drugs 2007; 16:367-379.
30. Gauler T, Fischer B, Soria J, et al. Phase II open-label study to investigate efficacy and safety of PTK787/ZK222584 orally administered once daily at 1,250mg as second-line monotherapy in patients with stage IIIB or stage IV non-small cell lung cancer. J Clin Oncol (ASCO Annual Meeting Proceedings I) 2006; 24:18S, abstract 7195.
31. Sarker D, Evans J, Hardie M, et al. A phase I, pharmacokinetic and pharmacodynamic study of CHIR-258, a novel oral multiple tyrosine kinase inhibitor. J Clin Oncol (ASCO Annual Meeting Proceedings I) 2006; 24:18S, abstract 3043.
32. Eskens F, Planting A, Van Doorn J, et al. An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 and -1 in a 4 week on, 2 week off schedule in patients with advanced solid tumors. J Clin Oncol (ASCO Annual Meeting Proceedings I) 2006; 24:18S, abstract 2034.
33. Kurup A, Lin C, Murry D, et al. Recombinant human angiostatin in combination with paclitaxel and carboplatin in patients with advance nonsmall-cell lung cancer: a phase II study from Indiana University. Ann Oncol 2006; 17:97-103.
34. Kulke M, Bergsland E, Ryan D, et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 2006; 24:3555-3561.
35. Rajkumar S, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24:431-436.
36. Stadtmauer E, Weber D, Dimopolous M, et al. Lenalidomide in combination with dexamethasone (Dex) is more effective than Dex alone at first relapse and provides better outcomes when used early rather than as later salvage therapy in relapsed multiple myeloma. J Clin Oncol (ASCO Annual Meeting Proceedings I) 2006; 24:18S, abstract 7600.
37. Schey S, Fields P, Bartlett J, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004; 22:3269-3276.
38. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
39. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3:65-71.
40. Folkman J, Ingber D. Inhibition of angiogenesis. Semin Cancer Biol 1992; 3:89-96.
41. Jain R. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62.
42. Karp J, Gojo I, Pili R, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-β-D-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res 2004; 10:3577-3585.
43. Wright J, Hagemann A, Rader J, et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 2006; 107:83-89.
44. Frangie C, Lefoucheur C, Mediani J, et al. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 2007; 8:177-178.
45. Hambleton J, Skillings J, Kabbinavar F, et al. Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. J Clin Oncol 2004: 252, abstract 3528.
46. Hambleton J, Skillings J, Kabbinavar F, et al. Safety of low-dose aspirin in a pooled analysis of 3 randomized, controlled trials of bevacizumab with chemotherapy in patients with metastatic colorectal cancer. J Clin Oncol 2005; 23(suppl):259S, abstract 3554.
47. Genentech. Avastin labeling text, FDA Approval Date:September 2005. http:// www.fda.gov/medwatch/SAFETY/2005/Jan_PI/Avastin_PI.pdf [accessed 3 April 2007].
48. Neagoe P, Lemieux C, Sirois M. Vascular endothelial growth factor (VEGF)-AI65-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer. J Biol Chem 2005; 280:9904-9912.
49. Rini B. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 2007; 13:1098-1106.
50. Perletti C, Concari P, Giardini R, et al. Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors. Cancer Res 2000; 60:1793-1796.
51. O'Reilly M, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79:315-328.
52. MacDonald N, Murad A, Fogler W, et al. The tumor-suppressing activity of angiostatin protein resides within Kringles 1 to 3. Biochem Biophys Res Commun 1999; 264:469-477.
53. Tuszynski G, Sharma M, Rothman V, et al. Angiostatin binds to tyrosinase substrate annexin II through the lysine-binding domain in endothelial cells. Microvasc Res 2002; 64:462-468.
54. Stack M, Gately S, Bafetti L, et al. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem J 1999; 340:77-84.
55. 2+ signaling in endothelial cells by the angiogenesis inhibitors endostatin and angiostatin. Am J Physiol Cell Physiol 2001; 280:C1140-C1150.
56. D'Amato R, Loughnan M, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91:4082-4085.
57. Knight R. IMiDs: a novel class of immunomodulators. Semin Oncol 2005; 32 (S5):S24-S30.
58. Scarpace S, Hahn T, Roy H, et al. Arterial thrombosis in four patients treated with thalidomide. Leuk Lymphoma 2005; 46:239-242.
59. Escudier B, Lassau N, Couanet D, et al. Phase II trial of thalidomide in renal cell carcinoma. Ann Oncol 2002; 13:1029-1035.
60. Hussein M. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost 2006; 95:924-930. This is an excellent current review of VTE management in multiple myeloma patients treated with IMiDs.
61. Zangari M, Elice F, Fink L, et al. Thrombosis in multiple myeloma. Expert Rev Anticancer Ther 2007; 7:307-315. This is a good review of the pathophysiology of thrombosis in multiple myeloma.
62. Horne M, Figg W, Arlen P, et al. Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer. Pharmacotherapy 2003; 23:315-318.
63. Corso A, Lorenzi A, Terulla V, et al. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol 2004; 83:588-591.
64. Kaushal V, Kaushal G, Melkaveri S, et al. Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. J Thromb Haemost 2004; 2:327-334.
65. Baz R, Liang L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005; 80:1568-1574.
66. Zonder J. Thrombotic complications of myeloma therapy. American Society of Hematology Education Book. Washington DC: American Society of Hematology 2006. pp. 348-355.
67. BelAiba R, Djordjevic T, Bonello S, et al. The serum- and glucocorticoid-inducible kinase Sgk-1 is involved in pulmonary vascular remodeling: role in redox-sensitive regulation of tissue factor by thrombin. Circ Res 2006; 98:828-836.
68. Hussein M. Lenalidomide: patient management strategies. Semin Hematol 2005; 42:S22-S25.
69. Dimopoulus M, Spencer A, Attal M, et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma: results of a phase 3 study (MM-010). ASH Annual Meeting Abstracts. Blood 2005; 106:abstract 6.
70. Knight R, DeLap R, Zeldis J. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006; 354:2079-2080.
71. Tobu M, Igbal O, Fareed D, et al. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Clin Appl Thromb Hemost 2004; 10:225-232.
72. Streetly M, Hunt B, Parmar K, et al. Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent actimid (CC-4047) and their relationship with venous thrombosis. Eur J Haemotol 2005; 74:293-296.
73. Celgene. Lenalidomide labeling text, FDA Approval Date:June 2006. http:// www.fda.gov/medwatch/safety/2006/Jun_PIs/Revlimid_PI.pdf [accessed 3 April 2007].
74. Celgene. Thalidomide labeling text, FDA Approval Date:May 2006. http:// www.fda.gov/medwatch/SAFETY/2006/May_PIs/Thalomid_PI.pdf [accessed 3 April 2007].
75. Rajkumar S, Jacobus S, Callander N, et al. A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. ASH Annual Meeting Abstracts. Blood 2006; 108:799.
76. Rustin G, Galbraith S, Anderson H, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003; 21:2815-2822.
77. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002; 12:3408-3416.
78. Patel S, Keohan M, Saif M, et al. Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. Cancer 2006; 107:2881-2887.
79. Tamura K, Nakagawa K, Kurata T, et al. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses. Cancer Chemother Pharmacol 2007; 60:285-293.
80. Beerepoot L, Radema S, Witteveen E, et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent ZD6126, in patients with solid tumors. J Clin Oncol 2006; 24:1491-1498.
81. McKeage M, Fong P, Jeffery M, et al. 5,6-Dimethylxanthenone-4- acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin Cancer Res 2006; 12:1776-1784.
82. Stewart D, Jonker D, Goel R, et al. Final clinical and pharmacokinetic results from a phase 1 study of the novel n-cadherin antagonist, exherin (ADH-1), in patients with refractory solid tumors stratified according to N-cadherin expression. J Clin Oncol (ASCO Annual Meeting Proceedings I) 2006; 24:18S, abstract 3016.
83. Sessa C, Perotti A, Maur M, et al. An enriched phase I, pharmacokinetic and pharmacodynamic study of the N-cadherin cyclic competitive binder exherin (ADH-1) in patients with solid tumors. J Clin Oncol (ASCO Annual Meeting Proceedings I) 2006; 24:18S, abstract 3042.
84. Denekamp J, Hill S. Angiogenic attack as a therapeutic strategy for cancer. Radiother Oncol 1991; 20 (S1):103-112.
85. Cooney M, van Heeckeren W, Bhakta S, et al. Drug insight: vascular disrupting agents and angiogenesis-novel approaches for drug delivery. Nat Clin Pract Oncol 2006; 3:682-692. This is a good review of vascular disrupting agents, pathophysiology, clinical trials, and future directions.
86. van Heeckeren W, Bhakta S, Ortiz J, et al. Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists? J Clin Oncol 2006; 24:1485-1488. This editorial discusses current models for cardiac toxicities of VDAs.
87. Zhao L, Ching L, Kestell P, et al. Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): increased tumor vascular permeability. Int J Cancer 2005; 116:322-326.
88. Lee A, Levine M, Baker R, et al. Randomized comparison of low-molecular-weight heparin versus oral anticoagulation therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators. N Engl J Med 2003; 349:146-153.
89. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162:1729-1735.